Form 3 Cyteir Therapeutics, For: Jun 17 Filed by: Secrist John Paul

June 17, 2021 9:17 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Secrist John Paul

(Last) (First) (Middle)
128 SPRING ST, BUILDING A, SUITE 510

(Street)
LEXINGTON MA 02421

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/17/2021
3. Issuer Name and Ticker or Trading Symbol
Cyteir Therapeutics, Inc. [ CYT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 07/21/2030 Common Stock 55,151 1.19 D  
Stock Option (Right to Buy)   (2) 07/21/2030 Common Stock 220,605 1.19 D  
Stock Option (Right to Buy)   (3) 02/21/2031 Common Stock 102,927 7.09 D  
Explanation of Responses:
1. The option vests as to 75% of the underlying shares of common stock on June 15, 2023, and as to the remaining shares underlying the award in 12 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
2. The option vested as to 25% of the underlying shares of common stock on June 15, 2021, and as to the remaining shares underlying the award in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
3. The option vests as to 1/3rd of the underlying shares of common stock on February 5, 2022, the first anniversary of the of the vesting commencement date, and at a rate of 1/36th of the underlying shares of common stock at the end of each subsequent monthly anniversary of the vesting commencement date until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
By: /s/ Andrew Gengos, Attorney-in-Fact 06/17/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                           LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints Andrew Gengos and David
Gaiero, and each of them individually, with full power of substitution, as the
undersigned's true and lawful attorney-in-fact to:

        (1) prepare, execute in the undersigned's name and on the undersigned's
            behalf, and submit to the U.S. Securities and Exchange Commission
            (the "SEC") a Form ID, including amendments thereto, and any other
            documents necessary or appropriate to obtain codes and passwords
            enabling the undersigned to make electronic filings with the SEC of
            reports required by Section 16(a) of the Securities Exchange Act of
            1934, as amended, or any rule or regulation of the SEC;

        (2) execute for and on behalf of the undersigned, in the undersigned's
            capacity as officer and/or director of Cyteir Therapeutics, Inc.
            (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
            accordance with Section 16(a) of the Securities Exchange Act of
            1934, as amended, and the rules thereunder;

        (3) do and perform any and all acts for and on behalf of the undersigned
            that may be necessary or desirable to complete and execute any such
            Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any
            amendment or amendments thereto, and timely file such form with the
            SEC and any stock exchange or similar authority; and

        (4) take any other action of any type whatsoever in connection with the
            foregoing that, in the opinion of each such attorney-in-fact, may be
            of benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by each
            such attorney-in-fact on behalf of the undersigned pursuant to this
            Power of Attorney shall be in such form and shall contain such terms
            and conditions as each such attorney-in-fact may approve in each
            such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or each such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted.  The undersigned acknowledges that each
foregoing attorney-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 18th day of May, 2021.

                                        /s/ John Paul Secrist
                                        ---------------------------
                                        Name: John Paul Secrist, Ph.D.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings